Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP1 | P29972 | 3/20 | 0.59 |
| ▸ | DPP4 | P27487 | 10/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.33 |
| ▸ | FADS1 | O60427 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965170 | 0.90 | AQP1 (0.47) | AQP1KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL6105035 | 0.88 | AQP1 (0.47) | AQP1DPP4KDM4EHTR2AHTR2C | |
| SCHEMBL4960551 | 0.86 | AQP1 (0.43) | AQP1DPP4TP53SMN1; SMN2HTR2A | |
| SCHEMBL4960260 | 0.84 | AQP1 (0.41) | AQP1HTR2AHTR2CHTR2B | |
| SCHEMBL8225498 | 0.81 | AQP1 (0.43) | AQP1DPP4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4960764 | 0.81 | AQP1 (0.47) | AQP1HTR2AHTR2CHTR2B | |
| SCHEMBL4964730 | 0.81 | AQP1 (0.47) | AQP1HTR2AHTR2CHTR2B | |
| SCHEMBL4959837 | 0.81 | AQP1 (0.47) | AQP1HTR2AHTR2CHTR2B | |
| SCHEMBL4960191 | 0.81 | AQP1 (0.39) | AQP1HTR2AHTR2CHTR2B | |
| SCHEMBL8228610 | 0.80 | AQP1 (0.67) | AQP1DPP4KDM4ENPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871759-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006116158-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | AQP1 1697/4885DPP4 4254/4885KDM4E 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.